{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Number and proportion of subjects who experience a treatment-emergent Grade 3 or 4', 'laboratory abnormality', 'The proportion of subjects with a treatment-emergent, treatment-related adverse event', '(AE) consistent with a drug rash', 'Part 2 Secondary Endpoints:', 'Number and rate of HAE attacks', 'Durability of response (attack rate trend over time)', 'Number and proportion of days with angioedema symptoms', 'Use of HAE attack medications', 'Discontinuations due to lack of efficacy', 'Durability in AE-QoL questionnaire scores', 'Durability in EQ-5D-5L scores', 'Durability in TSQM scores', 'Durability in WPAI scores', 'Part 3 Primary Objective:', 'To evaluate the long-term safety and tolerability of BCX7353 administered QD over', 'a', '48- to up to 144-week administration period in subjects with HAE', 'Part 3 Secondary Objectives:', 'To assess the effectiveness (ie, HAE attack frequency over time) of BCX7353 over', 'a', '48- to up to 144-week administration period', 'To evaluate QoL and HAE disease activity of BCX7353 over a 48- to up to 144-week', 'administration period', 'To evaluate subject satisfaction with BCX7353 over a 48- to up to 144-week', 'administration period', 'Part 3 Primary Endpoints:', 'Number and proportion of subjects with a TEAE', 'Number and proportion of subjects who discontinue due to a TEAE', 'Number and proportion of subjects who experience a TESAE', 'Number and proportion of subjects who experience a Grade 3 or 4 TEAE', 'Number and proportion of subjects who experience a treatment-emergent Grade 3 or 4', 'laboratory abnormality', 'The proportion of subjects with a treatment-emergent, treatment-related AE consistent', 'with a drug rash', '7']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Part 3 Secondary Endpoints:', 'Number and rate of HAE attacks', 'Durability of response (attack rate trend over time)', 'Number and proportion of days with angioedema symptoms', 'Use of HAE attack medications', 'Durability in AE-QoL questionnaire scores', 'Durability in EQ-5D-5L scores', 'Durability in TSQM scores', 'Durability in WPAI scores', 'Methodology:', 'This is a randomized, placebo-controlled, double-blind, parallel-group, 3-part study. Part 1 is', 'designed to test the hypothesis that the HAE attack rate during 24 weeks of prophylactic BCX7353', 'treatment at 2 dosage levels will be less than that observed during 24 weeks of placebo. The primary', 'efficacy endpoint will be assessed after the last subject completes Part 1 (through Week 24). Part 2 is', 'designed to primarily evaluate the long-term safety of BCX7353 at 2 dosage levels. Part 3 is', 'open-label and designed to primarily evaluate the long-term safety of BCX7353. Parts 1, 2, and 3 will', 'be conducted in sequence, with Parts 2 and 3 conducted as continuous roll-overs from Parts 1 and 2,', 'respectively. All subjects will receive BCX7353 in Parts 2 and 3, including those randomized to', \"receive placebo in Part 1. Based on the results of the current study's Part 1 analysis of greater efficacy\", 'and no increase in safety or tolerability risk at the 150 mg dose vs. the 110 mg dose, all subjects will', 'be transitioned to the 150 mg dose of BCX7353 on or after their Week 48 visit, regardless of their', 'initial or Week 24 treatment allocation.', 'Part 1 (24-week evaluation of blinded efficacy and safety)', 'Patients with HAE Type 1 or 2 will be eligible for the study following assessment of data obtained', 'from screening procedures, including demonstration of a minimum number of attacks documented', 'during a prospective run-in period of 2 to 8 weeks from the date of the screening visit.', 'Treatment-eligible subjects will receive study drug (BCX7353 or placebo) in Part 1 of the study based', 'on randomization in a 1:1:1 (active: active: placebo) ratio into 1 of 3 treatment groups:', 'Group 1: BCX7353 110 mg administered orally QD for 24 weeks', 'Group 2: BCX7353 150 mg administered orally QD for 24 weeks', 'Group 3: Placebo administered orally QD for 24 weeks', 'Enrollment into treatment groups will be stratified by the baseline HAE attack rate (> 2 attacks/month', 'VS. <2 attacks/month).', 'Beginning at screening and through the Week 48 visit, details of acute attacks of angioedema will be', \"recorded in an electronic diary (e-diary). Attacks will be treated in accordance with the subject's\", 'normal standard of care. Treatment medications for angioedema attacks will not be provided by the', 'Sponsor.', 'Within approximately 2 business days of the end of each attack that occurs beginning at the screening', 'visit through the Week 48 visit, subjects will be contacted by the Investigator (or appropriately trained', 'designee) to discuss the clinical characteristics of the attack, any questions the Investigator has on the', 'entered data, or to gain additional attack details not included in the e-diary that the Investigator deems', '8']\n\n###\n\n", "completion": "END"}